Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Lim

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Diabetes, Obesity & Metabolism|August 22, 2024
Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled studyHood Thabit, Jose Rubio, Mini Karuppan, et al.
Journal for Immunotherapy of Cancer|January 12, 2026
Cell therapy in sarcoma: current landscape and future directionsTaha Koray Sahin, Theodora Germetaki, Deniz Can Guven, et al.
Future Oncology (London, England)|January 17, 2025
Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancerRitu Salani, Tirza Areli Calderón Boyle, Jonathan Lim, et al.
Oncology and Therapy|August 3, 2024
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World StudyDana M Chase, Soham Shukla, Julia Moore, et al.
Journal for Immunotherapy of Cancer|September 26, 2022
Loss of secreted gelsolin enhances response to anticancer therapiesKok Haw Jonathan Lim, Evangelos Giampazolias, Oliver Schulz, et al.
Oncology and Therapy|July 4, 2024
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH StudyBobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, et al.
Investigative Ophthalmology & Visual Science|January 20, 2011
Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMDSanjeewa S Wickremasinghe, Jing Xie, Jonathan Lim, et al.
BMC Genomics|March 15, 2006
NovelFam3000--uncharacterized human protein domains conserved across model organismsDanielle Kemmer, Raf M Podowski, David Arenillas, et al.
Microorganisms|July 27, 2024
Oral Microbiota Alterations in Subjects with SARS-CoV-2 Displaying Prevalence of the Opportunistic Fungal Pathogen <i>Candida albicans</i>Areej A Alfaifi, Johanna B Holm, Tristan W Wang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2025
Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA studyFloor J Backes, Tirza Areli Calderón Boyle, Jonathan Lim, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Diabetes, Obesity & Metabolism|August 22, 2024
Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled studyHood Thabit, Jose Rubio, Mini Karuppan, et al.
Journal for Immunotherapy of Cancer|January 12, 2026
Cell therapy in sarcoma: current landscape and future directionsTaha Koray Sahin, Theodora Germetaki, Deniz Can Guven, et al.
Future Oncology (London, England)|January 17, 2025
Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancerRitu Salani, Tirza Areli Calderón Boyle, Jonathan Lim, et al.
Oncology and Therapy|August 3, 2024
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World StudyDana M Chase, Soham Shukla, Julia Moore, et al.
Journal for Immunotherapy of Cancer|September 26, 2022
Loss of secreted gelsolin enhances response to anticancer therapiesKok Haw Jonathan Lim, Evangelos Giampazolias, Oliver Schulz, et al.
Oncology and Therapy|July 4, 2024
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH StudyBobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, et al.
Investigative Ophthalmology & Visual Science|January 20, 2011
Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMDSanjeewa S Wickremasinghe, Jing Xie, Jonathan Lim, et al.
BMC Genomics|March 15, 2006
NovelFam3000--uncharacterized human protein domains conserved across model organismsDanielle Kemmer, Raf M Podowski, David Arenillas, et al.
Microorganisms|July 27, 2024
Oral Microbiota Alterations in Subjects with SARS-CoV-2 Displaying Prevalence of the Opportunistic Fungal Pathogen <i>Candida albicans</i>Areej A Alfaifi, Johanna B Holm, Tristan W Wang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2025
Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA studyFloor J Backes, Tirza Areli Calderón Boyle, Jonathan Lim, et al.
Pageof 10